IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 201-225 out of 1202.

<< < 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 > >>

Public Release: 17-Dec-2014
Journal of the American Chemical Society
New class of synthetic molecules mimics antibodies
A Yale University lab has crafted the first synthetic molecules that have both the targeting and response functions of antibodies. The new molecules -- synthetic antibody mimics -- attach themselves simultaneously to disease cells and disease-fighting cells. The result is a highly targeted immune response, similar to the action of natural human antibodies.

Contact: Jim Shelton
james.shelton@yale.edu
203-432-3881
Yale University

Public Release: 17-Dec-2014
Nature
'Master regulator' gene -- long tied to autism disorders -- stimulates other genes in early brain development
Chemical modifications to DNA's packaging -- known as epigenetic changes -- can activate or repress genes involved in autism spectrum disorders and early brain development, according to a new study to be published in the journal Nature on Dec. 18.

Contact: David March
david.march@nyumc.org
212-404-3528
NYU Langone Medical Center / New York University School of Medicine

Public Release: 17-Dec-2014
Clinical Cancer Research
'Sugar-coated' microcapsule eliminates toxic punch of experimental anti-cancer drug
Johns Hopkins researchers have developed a sugar-based molecular microcapsule that eliminates the toxicity of an anticancer agent developed a decade ago at Johns Hopkins, called 3-bromopyruvate, or 3BrPA, in studies of mice with implants of human pancreatic cancer tissue. The encapsulated drug packed a potent anticancer punch, stopping the progression of tumors in the mice, but without the usual toxic effects.
NIH/National Cancer Institute, Rolf W. Gunther Foundation for Radiological Science, American Cancer Society, Virginia and D.K. Ludwig Fund for Cancer Research, Lustgarten Foundation

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Public Release: 17-Dec-2014
Cell Cycle
Orphan receptor proteins deliver 2 knock-out punches to glioblastoma cells
Two related proteins exert a lethal double whammy effect against glioblastoma cells when activated with a small molecule. Scientists say when activated, one protein, called the short form, stops glioblastoma cells from replicating their DNA, and the other, called the long form, prevents cell division if the DNA has already been replicated.
NIH/National Cancer Institute

Contact: Karen Teber
km463@georgetown.edu
Georgetown University Medical Center

Public Release: 17-Dec-2014
Journal of American Chemical Society
A new strategy for developing drugs to fight cancer and other diseases
Promising treatments known as biologics are on the market and under development for many serious illnesses such as cancer, but some of them come with high risks, even lethal ones. Now scientists have produced a novel class of molecules that could be as effective but without the dangerous side effects. They report their work on these compounds, which they tested on prostate cancer cells, in ACS' Journal of the American Chemical Society.
National Institutes of Health, Bristol-Myers Squibb

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society

Public Release: 17-Dec-2014
FASEB Journal
Study shows how breast cancer cells break free to spread in the body
More than 90 percent of cancer-related deaths are caused by the spread of cancer cells from their primary tumor site to other areas of the body. A new study has identified how one important gene helps cancer cells break free from the primary tumor.
National Science Foundation

Contact: Brett Israel
brett.israel@comm.gatech.edu
404-385-1933
Georgia Institute of Technology

Public Release: 17-Dec-2014
Cancer Research
Researcher to cancer: 'Resistance will be futile'
Turning the tables, Katherine Borden at the University of Montreal's Institute for Research in Immunology and Cancer has evoked Star Trek's Borg in her fight against the disease.
National Institutes of Health, Leukemia & Lymphoma Society, Canada Research Chair in Molecular Biology of the Cell Nucleus, Cole Foundation, National Council for Scientific Research Lebanon, Pharmascience

Contact: William Raillant-Clark
w.raillant-clark@umontreal.ca
514-343-7593
University of Montreal

Public Release: 17-Dec-2014
Science Translational Medicine
Lens-free microscope can detect cancer at the cellular level
UCLA researchers have developed a lens-free microscope that can be used to detect the presence of cancer or other cell-level abnormalities with the same accuracy as larger and more expensive optical microscopes.

Contact: Bill Kisliuk
bkisliuk@support.ucla.edu
310-206-0540
University of California - Los Angeles

Public Release: 16-Dec-2014
Genome Biology
Combining images and genetic data proves gene loss behind aggressive ovarian cancers
Cancer Research UK scientists have shown that loss of a gene called PTEN triggers some cases of an aggressive form of ovarian cancer, called high-grade serous ovarian cancer.
Cancer Research UK

Contact: Simon Shears
simon.shears@cancer.org.uk
Cancer Research UK

Public Release: 16-Dec-2014
Nature Communications
New technology directly reprograms skin fibroblasts for a new role
Scientists have discovered a way to repurpose fibroblasts into functional melanocytes, the body's pigment-producing cells. The technique has immediate and important implications for developing new cell-based treatments for skin diseases such as vitiligo, as well as new screening strategies for melanoma.
National Institutes of Health

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine

Public Release: 16-Dec-2014
JAMA
Effectiveness of drugs to prevent hepatitis among patients receiving chemotherapy
Among patients with lymphoma undergoing a certain type of chemotherapy, receiving the antiviral drug entecavir resulted in a lower incidence of hepatitis B virus (HBV)-related hepatitis and HBV reactivation, compared with the antiviral drug lamivudine, according to a study in the Dec. 17 issue of JAMA.

Contact: Tongyu Lin
tongyulin@hotmail.com
The JAMA Network Journals

Public Release: 16-Dec-2014
British Journal of General Practice
Study recommends GPs should be more open when referring patients for cancer investigations
GPs should consider a more overt discussion with patients when referring them for further investigation of symptoms which may indicate cancer, according to a paper published in the British Journal of General Practice.
National Institute for Health Research

Contact: Philippa Walker
philippa.walker@bristol.ac.uk
44-117-928-8086
University of Bristol

Public Release: 16-Dec-2014
Review of Scientific Instruments
Microwave imaging of the breast
Although currently available diagnostic screening systems for breast are effective at detecting early signs of tumors, they are far from perfect, subjecting patients to ionizing radiation and sometimes inflicting discomfort on women who are undergoing screening because of the compression of the breast that is required to produce diagnostically useful images. New research suggests a better, cheaper, and safer way to look for the telltale signs of breast cancer may be with microwaves.

Contact: Jason Socrates Bardi
jbardi@aip.org
240-535-4954
American Institute of Physics

Public Release: 16-Dec-2014
Gastrointestinal Endoscopy
Mayo Clinic physicians say high-definition scopes accurately assess polyps
It may not be necessary for experienced gastroenterologists to send polyps they remove from a patient's colon to a pathologist for examination, according to a large study conducted by physician researchers at the Jacksonville campus of Mayo Clinic.
Olympus Corporation of America

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-0746
Mayo Clinic

Public Release: 16-Dec-2014
Cancer Cell
Single genetic abnormality accelerates, removes the brakes on Ewing sarcoma tumor growth
The genetic abnormality that drives the bone cancer Ewing sarcoma operates through two distinct processes -- both activating genes that stimulate tumor growth and suppressing those that should keep cancer from developing.
Burroughs Wellcome Fund, Howard Hughes Medical Institute, Hyundai Hope on Wheels, NIH/National Human Genome Research Institute

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital

Public Release: 16-Dec-2014
Developmental Cell
Vessel research offers new direction to study how cancer spreads
Researchers have understood very little about how blood and lymphatic vessels form in the mammalian gut -- until now. A new Cornell University study reports for the first time how arteries form to supply the looping embryonic gut with blood, and how these arteries guide development of the gut's lymphatic system.
Cornell Center for Vertebrate Genomics, National Institutes of Health, March of Dimes.

Contact: Melissa Osgood
mmo59@cornell.edu
607-255-2059
Cornell University

Public Release: 16-Dec-2014
Proceedings of the National Academy of Sciences
Bacterial 'bunches' linked to some colorectal cancers
Researchers from Johns Hopkins have found that dense mats of interacting bacteria, called biofilms, were present in the majority of cancers and polyps, particularly those on the right side of the colon. The presence of these bacterial bunches, they say, may represent an increased risk for colon cancer and could form the basis of new diagnostic tests.
National Institutes of Health, Alexander and Margaret Stewart Trust, American Society of Colon and Rectal Surgeons, Merieux Institute

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Public Release: 16-Dec-2014
Circulation: Cardiovascular Interventions
Real-time radiation monitor can reduce radiation exposure for medical workers
It's a sound that saves. A 'real-time' radiation monitor that alerts by beeping in response to radiation exposure during cardiac-catheterization procedures significantly reduces the amount of exposure that medical workers receive, University of Texas Southwestern Medical Center researchers found.
US Department of Veterans Affairs, Dallas Veterans Affairs Research Corporation, Gilead, Medicines Company

Contact: Cathy Frisinger
cathy.frisinger@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center

Public Release: 15-Dec-2014
2014 San Antonio Breast Cancer Symposium
Research: Two drugs before surgery help women with triple-negative breast cancer
A breast cancer specialist and clinical researcher at Women & Infants Hospital of Rhode Island presented research yesterday at the 2014 San Antonio Breast Cancer Symposium showing that adding either the chemotherapy drug carboplatin or the blood vessel-targeting drug bevacizumab to the standard treatment of chemotherapy before surgery helped women who have the basal-like subtype of triple-negative breast cancer.

Contact: Susan McDonald
slmcdonald@wihri.org
401-681-2816
Women & Infants Hospital

Public Release: 15-Dec-2014
eLife
Proteins drive cancer cells to change states
A new study from the Massachusetts Institute of Technology implicates a family of RNA-binding proteins in the regulation of cancer, particularly in a subtype of breast cancer.
National Institutes of Health

Contact: Sarah McDonnell
s_mcd@mit.edu
617-253-8923
Massachusetts Institute of Technology

Public Release: 15-Dec-2014
Proceedings of the National Academy of Sciences
Long noncoding RNAs: A novel prognostic marker in older patients with acute leukemia
A new study shows that patterns of molecules called long noncoding RNAs might help doctors choose the least toxic, most effective treatment for many older patients with acute myeloid leukemia. AML occurs mainly in older patients and has a three-year survival rate of 5 to 15 percent.
NIH/National Cancer Institute, Brigham and Women's Hospital, Coleman Leukemia Research Foundation, Pelotonia Fellowship Program, Associazione Italiana Ricerca sul Cancro AIRC, Ministero della Istruzione Università e Ricerca

Contact: Darrell E. Ward
darrell.ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center

Public Release: 15-Dec-2014
Pediatrics
E-cigarettes may recruit lower risk teens to nicotine use
A new study finds that one-third of Hawaiian adolescents have tried e-cigarettes, half of whom have never used another tobacco product. This is markedly higher rate than in the continental US. This raises the possibility that e-cigarettes are recruiting lower risk adolescents, who otherwise would be less susceptible to tobacco product use.
NIH/National Cancer Institute

Contact: Kirk Cassels
kirk.A.Cassels@Hitchcock.org
603-653-6177
The Geisel School of Medicine at Dartmouth

Public Release: 15-Dec-2014
Gynecologic Oncology
UTMB study finds that Hispanic women less likely to survive endometrial uterine cancer
In the largest study to date evaluating outcomes of Hispanic women with endometrial uterine cancer, researchers at the University of Texas Medical Branch at Galveston have found that Hispanic women in the United States were significantly less likely to survive the cancer than non-Hispanic white women. The study is available online in the December issue of Gynecologic Oncology.

Contact: Molly Dannenmaier
mjdannen@utmb.edu
409-772-8790
University of Texas Medical Branch at Galveston

Public Release: 15-Dec-2014
Journal of American Chemical Society
Dartmouth researchers create 'green' process to reduce molecular switching waste
Dartmouth researchers have found a solution using visible light to reduce waste produced in chemically activated molecular switches, opening the way for industrial applications of nanotechnology ranging from anti-cancer drug delivery to LCD displays and molecular motors.

Contact: John Cramer
John.Cramer@Dartmouth.edu
603-646-9130
Dartmouth College

Public Release: 15-Dec-2014
Journal of Clinical Oncology
Herceptin found to improve long-term survival of HER2-positive breast cancer patients
VCU Massey Cancer Center physician-researcher Charles E. Geyer, Jr., M.D., was the National Protocol Officer for one component of a large national study involving two National Cancer Institute-supported clinical trials that demonstrated that trastuzumab significantly improves the long-term survival of HER-2 positive breast cancer patients.
National Institutes of Health, National Surgical Adjuvant Breast and Bowel Project, Breast Cancer Research Foundation, Genentech

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University

Showing releases 201-225 out of 1202.

<< < 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 > >>

  Search News Releases

     

 

EurekAlert!